Rivaroxaban—Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study
2010 ◽
Vol 159
(3)
◽
pp. 340-347.e1
◽
Keyword(s):
2017 ◽
Vol 120
(10)
◽
pp. 1837-1840
◽
Keyword(s):
2015 ◽
Vol 170
(4)
◽
pp. 675-682.e8
◽
Keyword(s):
2017 ◽
Vol 119
(12)
◽
pp. 1989-1996
◽
Keyword(s):